Science 37 has signed a strategic collaboration with global biopharmaceutical company UCB to improve clinical trial experience by facilitating more patient-friendly, technology-enabled trials at home.
Under the collaboration, Science 37’s cloud-based mobile research platform, Network Oriented Research Assistant (NORA) will be used to offer greater patient value to the people participating in the trials conducted by UCB.
The decentralised approach of NORA is expected to provide data that will be more representative of patients’ real-life experiences.
It further aims to reduce the duration of product development and allow the faster launch of certain treatments.
Initially, the partnership will focus on the areas of neurology and immunology.
The partnership is also expected to enable a more integrated study design process where the patient-centric mindset will help early protocol development.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Science 37 co-founder and CEO Noah Craft said: “We created Science 37 to uniquely combine telemedicine technology, decentralised physician networks, and in-house experienced clinical study staff to take on new and exciting research studies.”
The NORA platform is designed to allow end-to-end remote clinical trials and complies with the advanced industry quality and regulatory standards.
Science 37 has also developed the Metasite or ‘site-less’ model, which is designed to help researchers engage directly with trial participants through every stage of planning starting from screening and recruitment to data lock.
The model’s direct online connection enables greater retention of patients, increased diversity across trials, and faster recruitment.